Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Teleflex Incorporated
TFX
NYSE·Healthcare·Medical - Instruments & Supplies·Mkt cap $5.7B
$133.99
▲ +3.27%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$100.18 - $139.67
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 6.7% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Comprehensive medical device portfolio
- Global distribution network
- Strong brand reputation in healthcare
- Continuous product innovation
Bear Case
1 risk
- Average volatility.
Growth
Turning profitable
Expanding healthcare technology market
Value
Undervalued - trading well below Medical Devices peers
Momentum
Strong
+10.1% over 3m
Quality
Strong
Solid business
Dividend
Modest
1.05% yield
Smart-money signal
Who's buying TFX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Latest print - beat on both lines
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
MAY 7, 2026
Reported EPS of $1.39 vs $1.21 consensus (+14.9% surprise). Revenue of $548.3M vs $536.9M expected (+2.1%). Beat on both top and bottom lines.
EPS surprise · last 4Q
1 of 1 beats
Q2 26
+14.9%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+3%
-5%
+4%
+19%
-28%
-22%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$749.7M
$764.4M
$795.4M
$700.7M
$780.9M
$913.0M
$569.0M
$548.3M
Margins · last 8Q
Gross
—
Operating
—
Profit
-1.5%
Wall Street consensus
5 analysts · 60% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
60%
Hold
40%
Sell
0%
Median Price Target
$150.00
▲ +11.9% vs $133.99
Latest: Truist · May 11, 2026
3 analysts covering